PREMARIN - Medsafe

ADVANTAN Presentation Uses - Medsafe

ADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.

  Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate

LOXALATE 1. Product Name - Medsafe Home Page

Page 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.

  Risks, Combination

DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …

New Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …

  Sheet, Data, Data sheet, Clexane

SEPTANEST Articaine hydrochloride 4% with …

SEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.

  Articaine

BOOSTRIX - Medsafe Home Page

1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.

  Information, Boostrix

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a

  Cymevene

Edition Draft - Medsafe

Part 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for

  Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice

Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …

New Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …

  Product, Name, Sheet, Data, Data sheet 1 product name

NEW ZEALAND DATA SHEET MESTINON® - Medsafe

NEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to

  Myasthenia, Gravis, Myasthenia gravis, Mestinon

DATA SHEET PREDNISONE - Medsafe

• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since

  Myasthenia, Gravis, Myasthenia gravis, Prednisone

ACG Clinical Guideline: Management of Patients with Acute ...

colon can present with melena (black, tarry stools) (5). In addition, hematochezia can be seen in patients with brisk upper gastrointestinal bleeding (UGIB).

PAR Clopidogrel 75 mg film-coated tablets PL 36390/0084

This is a summary of the Public Assessment Report (PAR) for Clopidogrel 75 mg film-coated tablets. It explains how Clopidogrel 75 mg film-coated tablets (PL 36390/0084, previously PL …

  Tablets, Coated, Film, Clopidogrel, Clopidogrel 75 mg film coated tablets pl 36390, 36390, Clopidogrel 75 mg film coated tablets, Pl 36390, Clopidogrel 75 mg film coated

HIGHLIGHTS OF PRESCRIBING INFORMATION thereafter or as ...

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV.

Page 1 of 4 BEVACIZUMAB Bevacizumab in combination with ...

A history of arterial thromboembolic events or age over 65 years was associated with an increased risk of developing arterial thromboembolic events during therapy.

  With, Events, Combination, Bevacizumab, Thromboembolic events, Thromboembolic, Bevacizumab bevacizumab in combination with

Management of the anticoagulated patient who presents …

Management of the anticoagulated patient who presents with intracranial haemorrhage Rebecca Appelboam, Exeter, UK Email: appelboamr@doctors.org.uk

  Patients, With, Management, Present, Intracranial, Anticoagulated, Management of the anticoagulated patient, Management of the anticoagulated patient who presents with intracranial haemorrhage, Haemorrhage

Topic 10: Patient safety and invasive procedures - WHO

Jun 13, 2002 · 216 Topic 10: Patient safety and invasive procedures Why patient safety is relevant to surgery and invasive procedures There is now plenty of evidence to show that

  Patients, Safety, Procedures, Invasive, Patient safety and invasive procedures

Warfarin Reversal Guideline 2012 - SurgicalCriticalCare.net

3 devices. The mortality rate in these patients was 30% (50/168). Thirty-six of the 50 deaths (72%) were attributed to the thromboembolic event (10)

  Guidelines, Warfarin, Reversal, Thromboembolic, Warfarin reversal guideline

Efficacy and safety of early parenteral anticoagulation as ...

Dec 04, 2014 · © Schattauer 2014 Thrombosis and Haemostasis 112.6/2014 Blood Coagulation, Fibrinolysis and Cellular Haemostasis 1120 Efficacy and safety of early parenteral ...

  Safety, Early, Parenteral, Anticoagulation, Safety of early parenteral anticoagulation as

HIGHLIGHTS OF PRESCRIBING INFORMATION **Doses up to …

CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of

  Cinryze